---
title: "Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | RLMD Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292895736.md"
description: "Relmada Therapeutics (Nasdaq: RLMD) announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026. The company plans to host a conference call and webcast at 4:30 PM ET to discuss the financial results for the quarter ended June 30, 2026, as well as recent business progress."
datetime: "2026-07-16T03:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292895736.md)
  - [en](https://longbridge.com/en/news/292895736.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292895736.md)
generator: "portal-rs"
---

# Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | RLMD Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Conference Call and Webcast Information:

-   Date: Thursday, August 6, 2026 at 4:30 PM ET
-   Participant Dial-in (US): 1-800-717-1738
-   Participant Dial-in (International): 1-646-307-1865
-   Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

**About Relmada Therapeutics, Inc.**  
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

**Investor Contact:**  
Brian Ritchie  
LifeSci Advisors  
britchie@lifesciadvisors.com

**Media Inquiries:**  
Corporate Communications  
media@relmada.com

### Related Stocks

- [RLMD.US](https://longbridge.com/en/quote/RLMD.US.md)

## Related News & Research

- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [ZTO Express Q2 2026 Earnings Preview](https://longbridge.com/en/news/296149351.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**